BECLOMETASONE CHIESI 400 microgrammes/1 ml, suspension pour inhalation par nébuliseur

( ARTG ) Asthma CIPLA BECLOMETASONE/FORMOTEROL is indicated in adults (18 years and older) in the treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids (ICS) and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both ICS and long-acting beta2-agonists (LABA). (See Section 4.2 Dose and method of administration DOSE AND METHOD OF ADMINISTRATION for treatment approaches). COPD (CIPLA BECLOMETASONE/FORMOTEROL 100/6 only) Symptomatic treatment of adults with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.